Journal of Nuclear Medicine · 2011 · 163 citations · 30 references
MedicineNuclear MedicineOncologyDiagnostic RadiologyPediatric OncologyRadionuclide TherapyPediatric Nuclear ImagingPediatric Nuclear MedicinePediatric Oncology ImagingPediatric Radiation OncologyRadiation TherapyMolecular Imaging For RadiotherapyNeuroblastoma RadiotherapyPediatric Neuroblastoma ImagingPediatric RadiotherapyPediatric Tumor ImagingRefractory NeuroblastomaRefractory Solid Tumors
UNLABELLED: This study tested the principle that (68)Ga-DOTATATE PET/CT may be used to select children with primary refractory or relapsed high-risk neuroblastoma for treatment with (177)Lu-DOTATATE and evaluated whether this is a viable therapeutic option for those children. METHODS: Between 2008 and 2010, 8 children with relapsed or refractory high-risk neuroblastoma were studied with (68)Ga-DOTATATE PET/CT. The criterion of eligibility for (177)Lu-DOTATATE therapy was uptake on the diagnostic scan equal to or higher than that of the liver. RESULTS: Of the 8 children imaged, 6 had abnormally high uptake on the (68)Ga-DOTATATE PET/CT scan and proceeded to treatment. Patients received 2 or 3 administrations of (177)Lu-DOTATATE at a median interval of 9 wk and a median administered activity of 7.3 GBq. Of the 6 children treated, 5 had stable disease by the response evaluation criteria in solid tumors (RECIST). Of these 5 children, 2 had an initial metabolic response and reduction in the size of their lesions, and 1 patient had a persistent partial metabolic response and reduction in size of the lesions on CT, although the disease was stable by RECIST. One had progressive disease. Three children had grade 3 and 1 child had grade 4 thrombocytopenia. No significant renal toxicity has been seen. CONCLUSION: (68)Ga-DOTATATE can be used to image children with neuroblastoma and identify those suitable for molecular radiotherapy with (177)Lu-DOTATATE. We have shown, for what is to our knowledge the first time, that treatment with (177)Lu-DOTATATE is safe and feasible in children with relapsed or primary refractory high-risk neuroblastoma. We plan to evaluate this approach formally in a phase I-II clinical trial.
30
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 1.1K citations
Katherine K. Matthay, C. Patrick Reynolds, Robert C. Seeger et al. · Journal of Clinical Oncology · 2009 · 856 citations
Medicine, Oncology, Chemotherapy +6